Tiburio is dedicated to developing transformative treatments for rare endocrine diseases. The company is advancing two dopamine somatostatin chimeric compounds. TBR-760 has the potential to be the first and only drug treatment for nonfunctioning pituitary adenomas. TBR-065 is a dopamine somatostatin chimeric compound that has been evaluated in a phase I clinical trial, for which Tiburio is currently exploring appropriate rare endocrine indications.